Drugs / tvs-CTL Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02482532 | Oct 2016 → Oct 2019 | melanoma | Gary Doolittle | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tvs-CTL Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02482532 ↗ |
| Action | Deplete | “find and destroy metastatic melanoma tumor” NCT02482532 ↗ |
| Modality | Cell therapy | “modified T-cells” NCT02482532 ↗ |